secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0000950170-24-076339
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M
------------------------------------------------------------------

- Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.
- Total purchase price $35.1M plus determined cure costs capped at $277,703.63.
- Transaction subject to Bankruptcy Court approval; Eiger filed Chapter 11 on April 1, 2024.
- Deal includes assigned contracts and regulatory filings; closing expected after court order.
- Amylyx deposits $1.755M into escrow as deposit per approved bid procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024076339/0000950170-24-076339-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017024076339/amlx-20240621.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-076339

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer